We are live on ! Find out more
CERO

CERo Therapeutics
CERO

Delisted

CERO was delisted on the 30th of October, 2025.

Back to rankings

65 hedge funds and large institutions have $159M invested in CERo Therapeutics in 2022 Q3 according to their latest regulatory filings, with 18 funds opening new positions, 16 increasing their positions, 6 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

260% more first-time investments, than exits

New positions opened: 18 | Existing positions closed: 5

167% more repeat investments, than reductions

Existing positions increased: 16 | Existing positions reduced: 6

25% more funds holding

Funds holding: 52 → 65 (+13)

7% more capital invested

Capital invested by funds: $149M → $159M (+$10.2M)

0% more ownership

Funds ownership: 0.04% → 0.04% (+0%)

Holders
65
Holders Change
+13
Holders Change %
+25%
% of All Funds
1.12%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
18
Increased
16
Reduced
6
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Janus Henderson Group
Janus Henderson Group
United Kingdom
+$11.8M
2
HSBC Holdings
HSBC Holdings
United Kingdom
+$4.71M
3
MF
Magnetar Financial
Illinois
+$3.2M
4
Marshall Wace
Marshall Wace
United Kingdom
+$2.14M
5
MC
Meteora Capital
Florida
+$1.65M

Top Sellers

Rank Fund Capital Flow
1
CF
Cantor Fitzgerald
New York
-$7.51M
2
HIM
HGC Investment Management
Ontario, Canada
-$5.04M
3
LA
Linden Advisors
New York
-$4.71M
4
WP
Woodline Partners
California
-$3.01M
5
CL
CSS LLC
Illinois
-$2.77M
Name Holding Trade Value Shares
Change 		Change in
Stake
ACM
26
Atalaya Capital Management
New York
$2.02M -$2.52M -125 -56%
UOC
27
UBS O'Connor
Illinois
$1.93M -$201K -10 -10%
SRCM
28
Sage Rock Capital Management
New York
$1.86M – – –
Hudson Bay Capital Management
29
Hudson Bay Capital Management
Connecticut
$1.78M -$242K -12 -12%
MC
30
Meteora Capital
Florida
$1.66M +$1.65M +82 New
SOA
31
Sea Otter Advisors
Florida
$1.26M +$1.25M +62 New
Barclays
32
Barclays
United Kingdom
$1.07M – – –
KL
33
KIM LLC
Kansas
$1.01M – – –
JP Morgan Chase
34
JP Morgan Chase
New York
$1.01M +$1.01M +50 New
TCM
35
Tenor Capital Management
New York
$1.01M – – –
SCM
36
Shaolin Capital Management
Florida
$1M +$1.01M +50 New
SSA
37
Schonfeld Strategic Advisors
New York
$1M +$60.4K +3 +6%
BI
38
Bulldog Investors
New Jersey
$982K -$20.1K -1 -2%
MTCM
39
Mint Tower Capital Management
Netherlands
$807K +$806K +40 New
BCM
40
Basso Capital Management
Connecticut
$756K +$745K +37 New
CAPTRUST Financial Advisors
41
CAPTRUST Financial Advisors
North Carolina
$540K +$544K +27 New
RCM
42
Rivernorth Capital Management
Florida
$505K – – –
WA
43
Whitebox Advisors
Minnesota
$505K – – –
CC
44
Centiva Capital
New York
$425K – – –
LCM
45
Lynwood Capital Management
Ontario, Canada
$400K +$60.4K +3 +18%
Parallax Volatility Advisers
46
Parallax Volatility Advisers
California
$340K +$342K +17 New
LCM
47
Landscape Capital Management
New Jersey
$329K +$322K +16 New
LA
48
Linden Advisors
New York
$325K -$4.71M -234 -94%
DFCM
49
Dark Forest Capital Management
Puerto Rico
$322K – – –
VF
50
Virtu Financial
New York
$314K +$322K +16 New
1
2
3

CERO Hedge Fund Activity: Q3 2022 in Review

65 of the 5,806 institutional investors tracked by Wall St. Rank reported a position in CERo Therapeutics (CERO) for Q3 2022, worth a combined $159M — up 6.8% from $149M a quarter earlier.

Buyers outnumbered sellers: 18 funds opened new CERO positions and 5 closed out — a net gain of 13 holders — while 16 added to existing stakes and 6 trimmed.

The largest buyer was Janus Henderson Group, adding an estimated $11.8M. The largest seller was Cantor Fitzgerald, exiting entirely with an estimated $7.51M sold.

  • 65 institutional investors held CERo Therapeutics (CERO) as of Q3 2022, up from 52 in Q2 2022.
  • Funds reported $159M of CERo Therapeutics stock for Q3 2022, up 6.8% quarter-over-quarter.
  • 18 funds opened new CERo Therapeutics positions in Q3 2022 and 5 closed out, a net change of +13 holders.
  • The largest CERo Therapeutics buyer in Q3 2022 was Janus Henderson Group, an estimated $11.8M added.
  • The largest CERo Therapeutics seller in Q3 2022 was Cantor Fitzgerald, an estimated $7.51M sold.

Based on aggregated 13F filings for Q3 2022.